Home › Generics › Darolutamide

Darolutamide

1 INDICATIONS AND USAGE NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: non-metastatic castration-resistant prostate cancer (nmCRPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. ( 1 ) NUBEQA is indicated for the treatment of adult patients with: non-metastatic castration resistant prostate cancer (nmCRPC) metastatic castration-sensitive prostate cancer (mCSPC) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.

brands

Filter:

Sort:

Brand NameDosage FormCompanyStrengthPrice

◎Damid

Tablet

Eskayef Pharmaceuticals Ltd.

Beacon Pharmaceuticals PLC

300 mg

৳1400

per tablet

1–2 of 2 brands

Clinical Information

Indications

Damid is indicated for the treatment of patients with non-metastatic castration resistant prostate cancer.

Pharmacology

Darolutamide is an androgen receptor (AR) inhibitor. Darolutamide competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. A major metabolite, keto-darolutamide, exhibited similar in vitro activity to Darolutamide. In addition, Darolutamide functioned as a progesterone receptor (PR) antagonist in vitro (approximately 1% activity compared to AR). Darolutamide decreased prostate cancer cell proliferation in vitro and tumor volume in mouse xenograft models of prostate cancer.

Dosage & Administration

The recommended dose of Darolutamide is 600 mg (two 300 mg tablets) administered orally twice daily, equivalent to a total dose of 1200 mg. Swallow tablets whole with food. Advice patients to take any missed dose as soon as they remember prior to the next scheduled dose, and not to take two doses together to make up for a missed dose. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.

Side Effects

Fatigue Pain in extremity Rash

Drug Interactions

⚕

Always consult a registered doctor before taking any medicine. This information is for general knowledge only.

Combined P-gp and Strong or Moderate CYP3A Inducers : Avoid concomitant use of Damid with combined P-gp and strong or moderate CYP3A4 Inducers. Combined P-gp and Strong CYP3A4 Inhibitors : Concomitant use of Damid with a combined P-gp and strong CYP3A4 inhibitor increases Damid exposure which may increase the risk of Damid adverse reactions. Monitor patients more frequently for Damid adverse reactions and modify Damid dosage as needed. BCRP (Breast Cancer Resistant Protein) Substrates : Avoid concomitant use with drugs that are BCRP substrates where possible. If used together, monitor patients more frequently for adverse reactions and consider dose reduction of the BCRP substrate drug.